| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
FPH Stock Overview
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems worldwide.
Rewards
Risk Analysis
FPH passed our risk checks.
Fisher & Paykel Healthcare Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NZ$29.35 |
| 52 Week High | NZ$36.55 |
| 52 Week Low | NZ$27.10 |
| Beta | -0.29 |
| 1 Month Change | -10.65% |
| 3 Month Change | -4.86% |
| 1 Year Change | -16.38% |
| 3 Year Change | 117.73% |
| 5 Year Change | 230.89% |
| Change since IPO | 6,422.22% |
Recent News & Updates
With EPS Growth And More, Fisher & Paykel Healthcare (NZSE:FPH) Is Interesting
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
Why The 41% Return On Capital At Fisher & Paykel Healthcare (NZSE:FPH) Should Have Your Attention
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...
Is Fisher & Paykel Healthcare (NZSE:FPH) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Shareholder Returns
| FPH | NZ Medical Equipment | NZ Market | |
|---|---|---|---|
| 7D | -6.8% | -5.3% | -3.2% |
| 1Y | -16.4% | -14.3% | -11.4% |
Return vs Industry: FPH underperformed the NZ Medical Equipment industry which returned -14.3% over the past year.
Return vs Market: FPH underperformed the NZ Market which returned -11.4% over the past year.
Price Volatility
| FPH volatility | |
|---|---|
| FPH Average Weekly Movement | 4.2% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in NZ Market | 6.5% |
| 10% least volatile stocks in NZ Market | 2.4% |
Stable Share Price: FPH is not significantly more volatile than the rest of NZ stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: FPH's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1934 | 5,811 | Lewis Gradon | https://www.fphcare.com |
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems worldwide. It provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company offers Airvo 2, a humidified nasal high flow system; Optiflow, a nasal high flow therapy; and F&P 850 System, a noninvasive and invasive ventilation system.
Fisher & Paykel Healthcare Fundamentals Summary
| FPH fundamental statistics | |
|---|---|
| Market Cap | NZ$16.94b |
| Earnings (TTM) | NZ$520.50m |
| Revenue (TTM) | NZ$1.96b |
32.5x
P/E Ratio8.6x
P/S RatioIs FPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FPH income statement (TTM) | |
|---|---|
| Revenue | NZ$1.96b |
| Cost of Revenue | NZ$709.60m |
| Gross Profit | NZ$1.25b |
| Expenses | NZ$730.90m |
| Earnings | NZ$520.50m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
May 25, 2022
| Earnings per share (EPS) | 0.90 |
| Gross Margin | 63.81% |
| Net Profit Margin | 26.54% |
| Debt/Equity Ratio | 4.5% |
How did FPH perform over the long term?
See historical performance and comparisonDividends
1.1%
Current Dividend Yield43%
Payout RatioValuation
Is Fisher & Paykel Healthcare undervalued compared to its fair value and its price relative to the market?
32.54x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: FPH (NZ$29.35) is trading above our estimate of fair value (NZ$18.65)
Significantly Below Fair Value: FPH is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: FPH is poor value based on its PE Ratio (32.5x) compared to the Oceanic Medical Equipment industry average (22.7x).
PE vs Market: FPH is poor value based on its PE Ratio (32.5x) compared to the NZ market (18.8x).
Price to Earnings Growth Ratio
PEG Ratio: FPH is poor value based on its PEG Ratio (5.9x)
Price to Book Ratio
PB vs Industry: FPH is overvalued based on its PB Ratio (10.6x) compared to the XO Medical Equipment industry average (4.2x).
Future Growth
How is Fisher & Paykel Healthcare forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
5.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FPH's forecast earnings growth (5.5% per year) is above the savings rate (2.1%).
Earnings vs Market: FPH's earnings (5.5% per year) are forecast to grow slower than the NZ market (7.3% per year).
High Growth Earnings: FPH's earnings are forecast to grow, but not significantly.
Revenue vs Market: FPH's revenue (5.4% per year) is forecast to grow faster than the NZ market (4.8% per year).
High Growth Revenue: FPH's revenue (5.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: FPH's Return on Equity is forecast to be high in 3 years time (23.4%)
Past Performance
How has Fisher & Paykel Healthcare performed over the past 5 years?
27.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FPH has high quality earnings.
Growing Profit Margin: FPH's current net profit margins (26.5%) are higher than last year (24.4%).
Past Earnings Growth Analysis
Earnings Trend: FPH's earnings have grown significantly by 27.2% per year over the past 5 years.
Accelerating Growth: FPH's earnings growth over the past year (32.9%) exceeds its 5-year average (27.2% per year).
Earnings vs Industry: FPH earnings growth over the past year (32.9%) underperformed the Medical Equipment industry 57.5%.
Return on Equity
High ROE: FPH's Return on Equity (32.7%) is considered high.
Financial Health
How is Fisher & Paykel Healthcare's financial position?
Financial Position Analysis
Short Term Liabilities: FPH's short term assets (NZ$867.7M) exceed its short term liabilities (NZ$314.3M).
Long Term Liabilities: FPH's short term assets (NZ$867.7M) exceed its long term liabilities (NZ$140.3M).
Debt to Equity History and Analysis
Debt Level: FPH has more cash than its total debt.
Reducing Debt: FPH's debt to equity ratio has reduced from 11.4% to 4.5% over the past 5 years.
Debt Coverage: FPH's debt is well covered by operating cash flow (739.6%).
Interest Coverage: FPH's interest payments on its debt are well covered by EBIT (220.5x coverage).
Balance Sheet
Dividend
What is Fisher & Paykel Healthcare current dividend yield, its reliability and sustainability?
1.11%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: FPH's dividend (1.11%) isn’t notable compared to the bottom 25% of dividend payers in the NZ market (2.76%).
High Dividend: FPH's dividend (1.11%) is low compared to the top 25% of dividend payers in the NZ market (4.97%).
Stability and Growth of Payments
Stable Dividend: FPH is not paying a notable dividend for the NZ market, therefore no need to check if payments are stable.
Growing Dividend: FPH is not paying a notable dividend for the NZ market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: FPH is not paying a notable dividend for the NZ market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FPH's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.8yrs
Average management tenure
CEO
Lewis Gradon (60 yo)
5.75yrs
Tenure
NZ$3,993,417
Compensation
Mr. Lewis G. Gradon has been the Chief Executive Officer, Managing Director & Executive Director at Fisher & Paykel Healthcare Corporation Limited since April 1, 2016. He served as the Senior Vice Presiden...
CEO Compensation Analysis
Compensation vs Market: Lewis's total compensation ($USD2.69M) is about average for companies of similar size in the NZ market ($USD3.57M).
Compensation vs Earnings: Lewis's compensation has increased by more than 20% in the past year.
Leadership Team
Experienced Management: FPH's management team is seasoned and experienced (5.8 years average tenure).
Board Members
Experienced Board: FPH's board of directors are considered experienced (6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: FPH insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Fisher & Paykel Healthcare Corporation Limited's employee growth, exchange listings and data sources
Key Information
- Name: Fisher & Paykel Healthcare Corporation Limited
- Ticker: FPH
- Exchange: NZSE
- Founded: 1934
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: NZ$16.938b
- Shares outstanding: 577.12m
- Website: https://www.fphcare.com
Number of Employees
Location
- Fisher & Paykel Healthcare Corporation Limited
- 15 Maurice Paykel Place
- East Tamaki
- Auckland
- 2013
- New Zealand
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/23 06:01 |
| End of Day Share Price | 2022/01/21 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2021/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.